Find and Pitch Jounalists, Get Your Story Covered

Tags: Science Nature Podcast 2024 Computer science Machine learning

	Profile	Recent Articles on Subject
1	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma - about 1 month ago TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 7 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - about 1 year ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - about 1 year ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - about 1 year ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - about 1 year ago Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma - about 1 year ago Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma - about 1 year ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - about 1 year ago Positive Results for Odronextamab in Relapsed/Refractory DLBCL - about 1 year ago
2	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	STAT+: For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission - about 2 months ago
3	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	SABCS 2024: Harnessing the Power of Tumor-Infiltrating Lymphocytes to Revolutionize Breast Cancer Treatment - about 2 months ago New Strategies in SCLC and DLBCL Are Transforming the Treatment Landscape - 2 months ago
4	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Fixed-Duration Acalabrutinib and Venetoclax Regimens Redefine First-Line Treatment Options for Patients With CLL - about 2 months ago Managing Adverse Event Profiles for Three Bispecific Antibodies Approved for Lymphoma - 10 months ago Patients With CLL Present Heterogeneously - 12 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL - about 1 year ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - about 1 year ago
5	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL - about 2 months ago FDA Approves First CAR-T for Chronic Lymphocytic Leukemia - 11 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - about 1 year ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - about 1 year ago
6	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 5 months ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 10 months ago CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning - about 1 year ago Year in Review: Follicular Lymphoma - about 1 year ago
7	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Scottish medicines consortium approves CAR T-cell therapy for blood cancer - 3 months ago
8	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 7 months ago Brentuximab Vedotin Shows 37% Reduction in Risk of Death for DLBCL - 8 months ago Study: Mutation Found to Make Follicular Lymphoma More Susceptible to Experimental Drug - 10 months ago Study: Lymphoma Patients Recover Longer for Pneumonia - 11 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 11 months ago
9	Erin Hunter, Assistant Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	More than 80% of Patients with Diffuse Large B-cell Lymphoma Responded to Novel Therapeutic, according to the Results of a Preclinical Trial - about 1 year ago FDA Updates Label for Axicabtagene Ciloleucel for R/R LBCL Following Positive Long-Term Survival Data - about 1 year ago Hispanic Patients with Philadelphia (Ph)-Like B-cell Acute Lymphoblastic Leukemia Continue to Experience Poor Outcomes, According to Expert - about 1 year ago Drug Sequence Might Not Significantly Impact Survival Outcomes of Patients with Lymphoma - about 1 year ago Golidocitinib Demonstrates Significant Survival Benefits For Patients with Peripheral T-cell Lymphoma - about 1 year ago New Update Changes Terminology for Some Cutaneous Lymphomas - over 1 year ago
10	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	FDA Grants Priority Review to Expand Indication for Bristol Myers Squibb’s Breyanzi in CLL, SLL - about 1 year ago

Journalists covering Diffuse Large B Cell Lymphoma